ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Serum biomarker panel (GastroPanel) and slow-release L-cysteine (Acetium Capsule): Rational for the primary prevention of gastric cancer

Co-Organized Event 13th International Conference on Clinical Gastroenterology & Hepatology & 2nd International Conference on Digestive Diseases

Kari J Syrjanen

Biohit HealthCare, Finland

Posters & Accepted Abstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X-C1-059

Abstract
Statement of the Problem: The major risk factors of gastric cancer (GC) are Helicobacter pylori (HP) infection and atrophic gastritis (AG). It is possible to diagnose HP-infection and AG by serological testing with panel of biomarkers (GastroPanel�?®, Biohit Oyj, Finland): pepsinogen I (PGI), pepsinogen II (PGII), gastrin-17 (G-17) and HP-antibodies. Severe AG leads to acid-free stomach colonized by HP and other bacteria, producing acetaldehyde (Group I human carcinogen; IARC). Together with other conditions leading to acid-free stomach, or those exposing the subjects to increased concentrations of acetaldehyde, these subjects are at high-risk for gastric and esophageal cancer. Methodology & Theoretical Orientation: GastroPanel�?® is the first non-invasive diagnostic tool for dyspeptic symptoms, and for screening of asymptomatic subjects for the risks of GC. A novel formulation (Acetium�?® Capsule, Biohit) based on slow-release L-cysteine, designed to protect the stomach in these high-risk subjects by its capacity to eliminate carcinogenic acetaldehyde. Findings: The test results test are interpreted by a specially designed software (GastroSoft�?®) identifying eight diagnostic marker profiles. Of those, four represent purely functional disorders, while three others specify structural abnormalities, and one is typical to HP-infection. Its superb clinical performance was validated in two recent meta-analysis, and the test has excellent longitudinal predictive values for incident GC. Acetium�?® Capsule is a unique medical device designed to elimination of carcinogenic acetaldehyde in the stomach among the high-risk subjects: AG associated with HP infection; autoimmune AG; cigarette smokers; alcohol consumers; chronic users of PPI medication, and those 500 million people in Asia with mutated ALDH2 enzyme exposed to higher local concentrations of acetaldehyde. Conclusion & Significance: With a rational use of these two medical devices, one can diagnose the gastric high-risk conditions and subsequently protect the stomach against acetaldehyde exposure.
Biography
Top